We are proud to share that our single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.
Building on those results, the data also suggest that humoral and cellular immune responses lasted through at least 8 months, the latest timepoint recorded in the study thus far.
EADAM named Awardee in Black Innovators in Skin Health QuickFire Challenge
Johnson & Johnson Innovation, together with Neutrogena®, recently announced that EADEM has been selected as the awardee in Black Innovators in Skin Health QuickFire Challenge. The challenge offered an opportunity for U.S.-based Black innovators working on potential skin and scalp health solutions to receive grant funding and mentorship.
How many of us were wondering what would happen in 2021 – the “post-Covid era”?
Hear from Dan Wang, Head of Johnson & Johnson Innovation in APAC who sees that while there are challenges there is a future of rising opportunities.